PILOT STUDY OF TOL, TOX & EFF OF BETA INTERFERON IN INCLUSION BODY MY

包涵体肌炎是一种炎症性肌病， 发病机制尚不清楚。 目前尚无有效的治疗方法。 本研究 假设免疫介导的肌肉损伤是原发性的， 次要的重要性，在生产肌肉无力和浪费， 这是IBM的特点。 虽然皮质类固醇和其他免疫抑制剂 药物治疗可能对某些患者有轻微的益处，他们通常 有效 免疫调节剂，特别是干扰素， 在一些炎症性疾病中有希望。 β-干扰素已经 被批准用于多发性硬化症，这种疾病的特征表明， 尚未明确的免疫发病机制，皮质类固醇是 有限的利益。 本研究将研究的耐受性和安全性， 肌肉注射β干扰素，并将确定问题， 完善各种肌肉测试程序，以优化其实用性， 主要结果指标。

Inclusion Body Myositis is an immflammatory myopathy whose precise pathogenesis is unknown. It has not effective treatment. This study hypothesizes that immune-mediated muscle damage is of primary or secondary importance in producing the muscle weakness and wasting that characterizes IBM. Although corticosteroids and other immune suppressant medication may be of minor benefit in some patients, they are generally effective. Immunomodulating agents, notably the interferons appear to hold promise in a number of inflammatory diseases. Beta interferon has been approved for use in multiple sclerosis, a disease with features suggesting a still-undefined immune pathogenesis and for which corticosteroids are of limited benefit. This study will investigate the tolerability and safety of intramuscular Beta interferon and will indentify problems with and refine the various muscle testing procedures to optimize their usefulness as primary outcome measures.